
TYRA
Tyra Biosciences Inc
Biotechnology
Tyra Biosciences Inc (TYRA) Stock News
The latest TYRA headlines and market coverage — 1 recent story, updated throughout the day.
- GlobeNewswire Inc.·
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
Pomerantz LLP is investigating potential securities fraud claims against Tyra Biosciences following the company's announcement of Phase 2 SURF302 study results for oral dabogratinib. Despite claims of a favorable safety profile, the study showed 14% and 9% of participants experienced Grade 3 adverse events in the 60mg and 50mg dose cohorts respectively. The announcement triggered a 17.66% stock price decline on September 9, 2026.